Biophysical Mechanism of Converting Apoptosis Regulator Bcl-2 from A Protector to A Killer in Cancer Cells by A Short Nur77-Derived Peptide

Xuefei Tian,Siva Kumar Kolluri,Xiuwen Zhu,Bingzhen Lin,Ya Chen,Dayong Zhai,Feng He,Zhi Zhang,John C. Reed,Arnold C. Satterthwait,Xiao-kun Zhang,Jialing Lin
DOI: https://doi.org/10.1016/j.bpj.2008.12.2732
IF: 3.4
2009-01-01
Biophysical Journal
Abstract:Bcl-2 can be converted into a pro-apoptotic molecule by nuclear receptor Nur77. The development of Bcl-2 converters as anti-cancer therapeutics has been explored by us. We reported recently the identification of a Nur77-derived Bcl-2 converting peptide (NuBCP) and its enantiomer, which induce apoptosis of cancer cells in vitro and in animals. The apoptotic effect of NuBCP enantiomers and their activation of Bax are not inhibited but rather potentiated by Bcl-2. Using fluorescence polarization assays, we determined that NuBCP enantiomers bind both quantitatively and stoichiometrically to the Bcl-2 loop, which shares the characteristics of structurally adaptable regions with many cancer-associated signaling proteins. NuBCP-9 enantiomers act as molecular switches to dislodge the Bcl-2 BH4 motif exposing its BH3 motif. Mechanistically we demonstrated, using fluorescence quenching based liposome assays, that NuBCP-9-induced Bcl-2 conformational change not only neutralizes Bcl-2's inhibition of Bax-mediated membrane permeabilization but also exposes the Bcl-2's BH3 motif that in turn neutralizes Bcl-XL's inhibition of Bax like BH3 motif-derived peptides and compounds. Our results provide mechanistic insight into Bcl-2 conversion and identify a new direction for developing Bcl-2-based cancer therapeutics. (This work is in part supported by the grant GM062964 to J. Lin from the National Institute of Health.)
What problem does this paper attempt to address?